• R ZuWallack, J Adelglass, D P Clifford, S P Duke, P D Wire, M Faris, and S M Harding.
• Saint Francis Hospital & Medical Center, Hartford, CT 06105, USA.
• Chest. 2000 Aug 1;118(2):303-12.

ObjectiveTo evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma.DesignDouble-blind, randomized, parallel group, and placebo-controlled phase (12 weeks) and an open-label phase (54 weeks).SettingMulticenter study in an outpatient setting.ParticipantsPatients (n = 253; age, > or = 12 years) with a mean FEV(1) of 67% predicted normal were stratified according to baseline therapy of maintenance inhaled corticosteroids vs beta(2)-agonists alone.Measurements And InterventionsFluticasone propionate (250 microg bid or 500 microg qd) or placebo (bid) was administered via the Diskus multidose powder inhaler (Glaxo Wellcome; Research Triangle Park, NC) for 12 weeks. During open-label treatment, patients were re-randomized to once-daily or twice-daily fluticasone propionate.ResultsCompared to placebo, fluticasone propionate administered qd or bid significantly improved FEV(1) (p < 0.001), morning (p < 0.001) and evening peak expiratory flow (PEF; p < 0.001), asthma symptom scores (p < or = 0.001), and albuterol use (p ConclusionsFluticasone propionate powder improved lung function when administered either qd or bid over a 1-year period to patients with moderate asthma, with twice-daily dosing demonstrating significantly greater improvement in some efficacy parameters than once-daily dosing over the first 12 weeks of treatment. Fluticasone propionate treatment was not associated with significant systemic effects.

32 keywords...

hide…